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ABSTRACT
Influence of Fibroblasts on Functional Arteriogenesis in a Murine Chronic Hindlimb
Ischemia Model
Ashli Agamata Santos
Peripheral arterial occlusive disease (PAOD) occurs when there is a narrowing or
blockage – usually a buildup of plaque - within the arteries that reduces blood flow to
tissues which can chronic ischemia. As with most diseases, early detection and proactive
treatment are important to maximize prognosis. Exercise effectively treats PAOD, but
due to ischemic pain in the limbs, or intermittent claudication (IC), exercise can become
painful and difficult. Due to the buildup of plaque, occlusions create an ischemic
environment that changes the pressure distribution in collateral networks and increases
the shear stress in transverse collaterals. Those two responses signal the beginning of
arteriogenesis- the enlargement of natural bypass collaterals, which can alleviate IC and
allow patients to exercise more comfortably. Arteriogenesis is controlled by macrophages
and growth factors to induce proliferation in endothelium and smooth muscles cells
(SMCs); enlarging arteries allow more blood to flow and oxygen to be transported. In this
study, fibroblast-containing collagen constructs were transplanted under the gracilis
muscle of mice with a ligated femoral artery to confirm their beneficial contribution to
arteriogenesis. Collagen constructs were also found to improve functionality of muscle
force production 7-days post femoral artery ligation. Though force-intensity found no
statistical significant between collagen constructs and fibroblast-containing collagen
constructs, they were both found to be an improvement from the baseline disease state.
Force-frequency data found fibroblast-containing collagen constructs to be an
improvement from the baseline disease state while being similar to the control, nondisease state. The PowerLab data acquisition unit (DAQ) and force transducer set-up is a
novel method to quantify the efficacy of myogenic cells to functionally treat ischemic
diseases and optimistic results of this study along with research based data acquisition
improvements suggest more robust and meaningful results in a multi-operator class
setting.
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Chapter 1: INTRODUCTION
Clinical Relevance
Cardiovascular (CV) disease in the leading cause of death globally and accounts
for 17.3 million deaths per year, and is expected to grow to 23 million by 2030 [24].
According to the American Heart Association, CV diseases “kill more people than all
forms of cancer combined” with costs totaling to be more than $320.1 billion [24].
Coronary Heart Disease (CHD) is the most common type of CV disease that kills
370,000 people and affects 735,000 in America alone [4]. Another CV disease, peripheral
arterial occlusive disease (PAOD), affects 8-12 million Americans each year and evenly
affects men and women [12]. The sheer number of people affected by ischemic disease
and the fact that current treatments for ischemic diseases are inadequate and not
applicable to the entire patient population warrant further research of therapies that mimic
or promote the body’s innate response to ischemia.

Peripheral Arterial Occlusive Disease and Atherogenesis
PAOD occurs when there is a narrowing or blockage within the arteries that carry
blood from the heart to extremities and is usually due to the buildup of plaque along
artery walls (Figure 1). Although PAOD equally affects men and women, the occurrence
increases with age. Other risk factors for PAOD include smoking, high blood, pressure,
diabetes, and high cholesterol [5]. The buildup of plaque is referred to as atherogenesis
and can lead to chronic ischemia-insufficient blood flow to tissues that impairs
microcirculation function. A common symptom of PAOD is pain in the leg while doing
physical activity; however, up to 40% of patients do not have leg pain [5]. Due to this,
1

PAOD can go undiagnosed until more serious symptoms like muscle atrophy, hair loss,
or non-healing ulcers [25].

Figure 1: Peripheral Arterial Occlusive Disease
PAOD is the narrowing of peripheral arteries, more commonly legs than arms, due to atherosclerotic
plaques build-up [11].

Current Treatments of PAOD
Like most diseases, early diagnosis and treatment are critical. If diagnosed early,
dietary and lifestyle changes may reduce symptoms and halt further progression of the
disease. Treatments also commonly include regular physical exercise, a low-fat diet, and
smoking cessation. These changes can decrease cholesterol levels and lower blood
pressure. Other common treatments focus on medications to manage inflammation, lipid
levels, and prevent blood clots.
In more serious cases, endovascular intervention such as stenting, or bypass surgery may
be required. Endovascular treatment is a minimally invasive procedure that uses
catheters, wires, and even stents to treat the atherosclerotic arteries (Figure 2). With
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advances in imaging, equipment, and endovascular expertise, endovascular treatments
have become more popular due to its outpatient nature and low cost [1].

Figure 2: Stenting as an Endovascular Treatment
A stent is guided to the atherosclerotic part of the artery using catheter. Once the closed stent is in the
correct area the stent is expanded using a balloon. Once fully expanded, the stent is left in place to allow
better blood flow past the compressed plaque. [20].

Arteriogenesis and Vascular Remodeling
During arteriogenesis – a body’s innate response to ischemia - endothelial and
smooth muscle cells of existing micro vessels are stimulated to proliferate and outward
remodeling occurs (Figure 3). This remodeling thereby enlarges natural bypasses to
supply blood and oxygen to tissues downstream of the occluded artery. The presence of
enlarged collaterals is a favorable prognostic factor and can increases a patient’s chances
of recovery [3228]. Through understanding the physiology of ischemic disease,
fibroblasts have been identified as an important therapeutic target.
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Figure 3: Overview of Arteriogenesis
Under ischemic conditions the body can naturally respond with arteriogenesis. A –Under normal
conditions, existing collaterals are smaller in diameter. B – When plaque begins to build up, the pressure
within the system changes causing an increase of stress in the collaterals. D – The changes in environment
activate a series of events that increase the diameter of collaterals to restore the difference in pressure. [10].

Ischemic disease can cause insufficient blood flow to the brain, heart, or legs
which can lead to stroke, myocardial infarction, or amputation due to infection,
respectively; it is also accountable for millions of deaths worldwide. Ischemic diseases
result from insufficient blood flow to tissues that results in necrosis, which weakens the
heart, kills brain tissue, or peripheral tissue.
Ischemia is not easily treated by just one gene, protein, or cell type but scientists
have found that there are synergistic benefits to therapies that combine multiple genes,
growth factors, or cells. After all pharmaceutical options are exhausted, stimulation of
vessel growth is considered. There are two forms of vessel growth: angiogenesis and
arteriogenesis. While angiogenesis refers to the formation of new capillary networks,
arteriogenesis refers to the growth of preexisting collaterals.
Arteriogenesis occurs when an arterial occlusion decreases downstream pressure
and increases the shear stress in transverse collaterals. The increased shear stress
activates endothelial cells causing an upregulation of cell adhesion molecules for
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monocytes. The monocytes then differentiate into macrophages that secrete growth
factors that stimulate the proliferations of endothelial and smooth muscle cells to increase
the diameter of existing collaterals (Figure 4).

Figure 4: Molecular Mechanism of Arteriogenesis
Within the first 24 hours of an arterial occlusion, 1) changes in pressure increase shear stress within
collateral arteries therefore activating endothelial cells that 2) activates signaling pathways to express
multiple genes for monocyte attraction, activation and adhesion. The monocytes 3) are then transformed to
macrophages that secrete growth factors to 4) stimulate smooth muscles cell proliferation [31]

Previous Work Regarding Arteriogenesis
As with many process within the body, there are a multitude of growth factors
involved with the proliferation of smooth muscle cells (SMCs) in arteriogenesis [29].
Growth factors like fibroblast growth factor (FGF), transforming growth factor beta
(TGF-B), platelet-derived growth factors (PDGF), insulin-like growth factor (IGF-I/II),

5

and monocyte chemoattractant protein-1 (MCP-1) regulate the proliferation of smooth
muscle cells [16].
Although the administration of isolated growth factors stimulates arteriogenesis in
animal models, they failed in clinical trials [3]. To maximize the therapeutic benefits of
arteriogenesis more studies are needed to determine the most effective growth factor(s),
optimal amount of the growth factor(s), when during remodeling process to administer
the factors, etc [13]. Since direct inject was ineffective in answering those logistical
questions, the next wave of research began transplanting cells that could naturally secret
the growth factors needed for arteriogenesis [28,13].
Fibroblasts are a therapeutic target because they synthesize and maintain the
matrix for vascular remodeling by controlling FGF expression [18]. Transplanted
fibroblast-cell sheets effectively repair or promote vascular regeneration in damaged
hearts of rats [17]. Fibroblasts and myoblasts – immature skeletal muscle cells –
constructs promote arteriogenesis in murine hindlimb chronic ischemia models [6,9].

Contractile and Kinetic Properties of Muscles
Every muscle type has different distributions of slow- and fast-twitch muscle
fibers; each of which produce different contractile properties and fatigue profiles. These
different fibers contribute to differences in power – or force production – and fatigue
properties [13]. Slow-twitch muscles are predominantly aerobic and used for endurance
activities; fast-twitch muscles are predominantly anaerobic and used for sprinting or
power exercise.

6

In general, force varies depending on the length of that muscle. Much like the
elastic properties in a rubber band, increased length of muscles increases active force
production and passive baseline tension (Figure 5).

Figure 5: Length-Tension Relationship
As a muscle is stretched, elastic properties increase active force production and passive baseline tension
[13].

Muscles are categorized as fast- or slow- twitch because of differences in kinetic
properties. Differences in fiber composition allows fast twitch muscles to reach max
force and relax quicker than slow twitch muscles (Figure 6).

Figure 6: Twitch Kinetics
Fiber compositions allow fast twitch muscles to reach max force and relax quicker than slow twitch
muscles [13].

A single stimulus produces a singular force output. Multiple stimuli – or tetanus –
produce different force-frequency relationships in the different muscle types (Figure 7).

7

The tetanus response curve can be manipulated even further by decreasing or increasing
the number of stimuli within a given period of time – or frequency (Figure 8).

Figure 7: Tetanus Kinetics
Multiple stimuli create force-frequency curves that differ significantly in shape between fast- and slowtwitch muscles [13].

Figure 8: Force-Frequency Relationship
Due to mechanical summation, an increase in frequency generally increases the amount of force production
[13].

In addition to force production measurements, another metric important to
assessing muscular functionality is muscle fatigue. Fatigue occurs when there is repetitive
stimulation over a longer period of time. Even though fast- and slow- twitch muscles
differ on many levels, the fatigue curves produce look very similar (Figure 9). The
quality that differentiates the two muscles types in the rate at which the force production
decreases. More energy is needed and therefore is used quicker in fast twitch muscles
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resulting in a faster rate of fatigue in comparison to the slower fatigue rate of slow twitch
muscles.

Figure 9: Fatigue Curve
In general, force production decrease with time but the rate at which it decreases differs due to energy
pathways and needs of the different muscle types [13].

Specific Aims
Animals, especially rodents, are commonly used to assess numerous diseases in
their natural progression along with the deviated progression due to novel therapeutic
interventions. Mice are commonly used because of their convenience and
inexpensiveness; they are small in size, can easily be housed and maintained, adapt well
to new environments, and reproduce quickly [22]. Once a treatment is effective in-vitro at
the cellular level, it must then be further tested to determine if its effectiveness in an
organism.
Considering muscle function heavily depends on the oxygen and nutrients
transported in blood, efficient and effective vascularization is important. Muscle function
can then be assessed using force production. Excised skeletal muscle was successfully
tested for isometric and eccentric force duration in muscular dystrophy murine models
using a data acquisition unit (DAQ) [23]. Muscular exhaustion – or fatigue – was tested
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in live mice using a forced treadmill protocol that measured total distance and speed at
the point of total exhaustion occurred [19].
Since myoblast have already been found to promote arteriogenesis, a class of 15
students tried to assess the functional efficacy of fibroblast-collagen constructs using
force production measurements. The fibroblast-collagen construct was statistically
different from all groups except for the collagen-only construct. Therefore, the specific
aim of this project is to:
1. Repeat class experiment but improve confidence in results by decreasing
statistical variation due to multiple operators and operating in a more
controlled environment.
2. Refine protocol to efficiently produce significant results given multiple
operators and strict time restraints.
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Chapter 2: MATERIALS AND METHODS
Animal Housing and Care
Male and female ICR mice along with female Swiss Webster mice were used in
the procedures in accordance with protocols approved by the Institutional Animal Care
and Use Committee (IACUC) of California Polytechnic State University, San Luis
Obispo. Mice were housed in the University Vivarium and were monitored daily for
food, water and additional enrichment factors (cage bedding, mouse house, and tunnel
tube).

Mouse Preparation
Mice were anesthetized in an induction chamber using 5% isoflurane in oxygen
flowing at 3-5 l·min-1. They were then subcutaneously administered buprenorphine
analgesic (0.075 mg·kg-1). After the initial anesthetization, mice were transferred to a
heating pad on a surgical slate and administered 1-3% isoflurane flowing at 0.8-1.0 l·
min-1 through a nose cone. The heating pad was set to maintain a core body temperature
of 35oC for the duration of the procedure using a rectal temperature probe. The hair on
the lower, ventral region of the mouse was removed prior to surgery with trimming
clippers and depilatory cream. Veterinary ointment was then applied to the corneas to
prevent desiccation. The entire mouse preparation protocol can be seen in Appendix A.

Femoral Artery Ligation
To model peripheral arterial occlusion (PAO), a femoral artery ligation was
performed in the hindlimb of a murine animal model. The entire procedure was
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performed under aseptic conditions to reduce contamination and infections. The initial
incision was made on the medial potion of the thigh and stopped at the abdominal wall
(Figure 10A). Using blunt dissection, surrounding connective tissue was removed and
the epigastric fat pad was retracted and reveal the neurovascular bundle. Connective
tissue above the bundle was gently removed to isolate the femoral artery; once it was
isolated 6-0 silk suture was used to ligate the femoral artery between the epigastric and
popliteal branches (Figure 10B). The entire femoral artery ligation protocol can be seen
in Appendix A.

A)

B)

Figure 10: Femoral Artery Ligation.
A – The initial incision was made on the medial aspect of the femur to the abdominal wall to expose the
epigastric fat pad and neurovascular bundle. B – The femoral artery was ligated between the epigastric and
popliteal branches.

Fibroblast Construct Transplantation and Suture
A premade pocket under the gracilis anterior muscle was created using blunt
dissection to house the collagen construct. The entire construct was then gently placed
beneath the muscle (Figure 11A). To prevent desiccation the entire surgical site was
irrigated with sterile phosphate buffered saline (PBS). The incision was then closed using
7-0 polypropylene monofilament suture (Figure 11B). The mouse was then
12

subcutaneously administered buprenorphine analgesic (0.075 mg·kg-1) again. Mice were
then returned to the University Vivarium to be monitored daily using ambulation scoring
until walking normally. The entire femoral artery ligation protocol can be seen in
Appendix A.

A)

B)

Figure 11: Fibroblast Construct Transplantation.
A – The entire fibroblast construct was gently tucked under the gracilis muscle. B – The surgical incision is
then sutured closed.

The surgical groups used for this study can be found in Table 1 below. Surgical
group 1 consisted of mice that were ligated and blunt dissected under the gracilis muscle
but did not receive a construct. Surgical group 2 consisted of mice that were ligated and
blunt dissected to receive a construct with no fibroblasts. Surgical group 3 consisted of
mice that were ligated and blunt dissected to receive a construct with fibroblasts.

Table 1: Experimental Design and Surgical Groups
Surgical Groups
Number of Mice Description
1
4
Ligated, Dissected, no construct
2
5
Ligated, Dissected, construct with no cells
3
5
Ligated, Dissected, construct with
fibroblasts
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Force Production and Gracilis Muscle Harvest
Seven days post-surgery, arteriogenesis was functionally tested using force
production measurements as seen in Appendix B. This was achieved using blunt
dissection to dorsally reflect the sciatic nerve, which was stimulated to contract the
gracilis muscle (Figure 12A). Once the nerve was reflected using parafilm, a curved
current electrode was attached. Then the Achilles tendon is exposed and silk suture is tied
to the end of the tendon (Figure 12B and Figure 12C). The suture is used to connect the
Achilles to a force transducer (Protocol in Appendix C). Measurements were taken for
force-intensity, force-frequency and fatigue.

A)

B)

C)

Figure 12: Force Production Set-Up.
A – The sciatic nerve is reflected using parafilm for ease of access. B – The Achilles tendon is then
exposed and silk suture is knotted to the end so it can be connected to the force transducer. C – The whole
force production set up is constructed to quantitatively measure an aspect of arteriogenesis.

Once measurements were taken, sodium nitroprusside (SNP) was applied to the
gracilis muscle to induce maximal vasodilation. After maximal dilation, the gracilis was
fixed in-situ for 15 minutes using paraformaldehyde (4% PFA) and covered with plastic
wrap to prevent desiccation. After fixation, the muscle was removed from surrounding
tissue and placed in more PFA overnight at 4oC. Once 24 hours have passed, they were
washed using and store in PBS at 4oC until stained.
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Staining and Imaging
Alpha smooth muscle-actin (-SMA) was used to stain and visualize the
collateral network throughout the muscle. A working solution of -SMA (1:200) was
prepared along with saponin (0.1%) and bovine serum albumin (BSA, 2%) in PBS. The
muscle was incubated in the stain for 3 nights. After the staining period, they were
washed in a saponin (0.1%) and PBS mixture three times and in PBS once. Finally, they
were mounted on glass slide. This staining protocol is in Appendix D.
A widefield fluorescent microscope was sued to visualize and image the muscle
using 550nm excitation and 570nm emission. Images of the stem, midzone, and re-entry
were captured at 4x or 10x magnification. Gracilis imaging protocol is in Appendix E.

Data and Statistical Analysis
The Data Pad function in Lab Chart Reader was used to obtain force production
and integral measurements and then exported to Microsoft Excel according to the
protocol in Appendix F. Microsoft Excel was then used to graphically display data while
ImagesJ was used to measure vessel diameters. Differences in force production, force
intensity, and fatigue along with percent change in diameter were determined by
ANOVA tests, a p<0.05 was used to indicate significance.

15

Chapter 3: RESULTS
The potential functional contribution of fibroblasts was tested by transplanting
fibroblast-containing collagen constructs into a mouse model with a ligated femoral
artery. The three groups tested were: ligated with no construct in the pocket, ligated with
collagen construct in the pocked, and ligated with a fibroblast-containing collagen
construct in the pocked. Force production measurements were taken regarding
stimulation intensity, stimulation frequency, and fatigue, and results are presented below.
The control group consists of the non-ligated leg of each mouse.

Force-Intensity
In general, across all treatment groups, force production increased with increased
stimulation intensity (Table 2). Overall, the pocket group was lower than the collagen
and fibroblast groups (Figure 13). With regards to various stimulation intensities, the
control group was greater than the pocket group between 0.75 and 4.5 mV.
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Table 2: Muscle Force Production with Increasing Intensity
Intensity
Force Production (mN/mg)
(mV)
Pocket
Collagen
Fibroblast
0.25
0.04 + 0.04
0.06 + 0.04
0.00 + 0.00
0.50
0.06 + 0.06
0.24 + 0.14
0.29 + 0.27
0.75
0.16 + 0.11
0.49 + 0.24
0.54 + 0.39
1.00
0.28 + 0.15
0.67 + 0.33
0.59 + 0.38
1.25
0.36 + 0.16
0.75 + 0.37
0.69 + 0.36
1.50
0.43 + 0.16
0.77 + 0.37
0.79 + 0.36
1.75
0.46 + 0.17
0.77 + 0.35
0.83 + 0.36
2.00
0.48 + 0.17
0.78 + 0.34
0.86 + 0.35
2.25
0.50 + 0.18
0.83 + 0.32
0.93 + 0.34
2.50
0.52 + 0.18
0.89 + 0.30
0.98 + 0.33
2.75
0.54 + 0.18
0.93 + 0.29
1.00 + 0.33
3.00
0.56 + 0.19
0.97 + 0.29
1.03 + 0.32
3.25
0.59 + 0.19
1.01 + 0.28
1.10 + 0.35
3.50
0.59 + 0.19
1.05 + 0.28
1.08 + 0.33
3.75
0.62 + 0.19
1.08 + 0.30
1.07 + 0.34
4.00
0.64 + 0.19
1.04 + 0.28
1.06 + 0.34
4.25
0.59 + 0.19
1.07 + 0.27
1.05 + 0.35
4.50
0.63 + 0.19
1.18 + 0.34
1.04 + 0.34

Control
0.18 + 0.10
0.54 + 0.14
0.94 + 0.11
1.06 + 0.10
1.14 + 0.10
1.17 + 0.11
1.20 + 0.13
1.17 + 0.15
1.21 + 0.12
1.28 + 0.13
1.30 + 0.13
1.34 + 0.12
1.31 + 0.10
1.38 + 0.12
1.43 + 0.12
1.45 + 0.12
1.51 + 0.13
1.47 + 0.12
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A)

B) 1.80
**

Force Production (mN/mg)

1.60
1.40
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1.20
1.00

*

Pocket + Collagen
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+ Fibroblast
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*

0.40
Control *

0.20
0.00
-0.50

**
0.50

1.50

2.50

3.50

4.50

Stimualtion Intensity (mV)
Figure 13: Muscle Force Production with Increasing Intensity
Force produced in measured for twitch recruitment of four sub-groups at increasing stimulation intensities:
.25, .50, .75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.25, 3.50, 3.75, 4.00, 4.25, and 4.50 mV. A
– Raw data trace of force production using a data acquisition unit that stimulated the sciatic nerve and
measured force using a force transducer attached to the Achilles tendon of a mouse. B – Averaged
normalized muscle force production, using individual gastrocnemius weights, for each treatment group at
increasing stimulation intensities (n=14 control, n=4 pocket, n=5 collagen, and n=5 fibroblasts). Data are
presented as mean ± SE. * denotes p < 0.05 for pocket vs collage/fibroblast vs control and ** denotes p <
0.05 for pocket vs control at 0.75mV to 4.5 mV.

Force-Frequency
In general, the control group and the fibroblast group were greater than pocket
group (Table 3). In most cases the stimulation frequency of 50 Hz produced the greatest
force production; excluding the collagen group which had higher force production in the
5Hz and 10 Hz frequency groups (Figure 14). At 50 Hz stimulation frequency only the
fibroblast group was significantly greater than the pocket group. At 2.5 Hz and 5 Hz
stimulation frequency, only the control group was significantly greater than the pocket
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group. In all the other stimulation frequency categories, no significant difference was
found among the groups.

Table 3: Muscle Force Production with Increasing Frequency
Freq.
Force Production (mN/mg)
(Hz)
Pocket
Collagen
Fibroblast
2.5
0.64 + 0.20
1.34 + 0.49
1.25 + 0.39
5.0
0.68 + 0.21
1.33 + 0.48
1.26 + 0.40
10.0
0.67 + 0.21
1.03 + 0.34
1.34 + 0.33
20.0
0.69 + 0.21
1.07 + 0.42
1.45 + 0.33
50.0
1.02 + 0.47
1.29 + 0.52
2.34 + 0.63

Control
1.80 + 0.15
1.80 + 0.16
1.25 + 0.22
1.31 + 0.24
1.88 + 0.40

A)

B)

3.50

##

Force Production (mN/mg)

3.00
2.50

#

**

Pocket *

2.00

##

1.50
1.00

Pocket + Collagen +
Fibroblast
Control

#

**

Pocket + Collagen

*

0.50
0.00
2.50

5.00

10.00

20.00

50.00

Stimualtion Frequency (Hz)
Figure 14: Muscle Force Production with Increasing Frequency
Force produced in measured for twitch recruitment of four sub-groups at increasing stimulation
frequencies: 2.50, 5.00, 10.00, 20.00, and 50.00 Hz. A – Raw data trace of force production using a data
acquisition unit that stimulated the sciatic nerve and measured force using a force transducer attached to the
Achilles tendon of a mouse. B – Averaged normalized muscle force production, using individual
gastrocnemius weights, for each treatment group at increasing stimulation frequencies (n=14 control, n=4
pocket, n=4 collagen, and n=4 cells). Data are presented as mean ± SE. * denotes p < 0.05 for pocket vs
fibroblast/control, ** denotes p < 0.05 for pocket vs control at 2.5 Hz, # denotes p < 0.05 for pocket vs
control at 5.0 Hz, and ## denotes p < 0.05 for pocket vs fibroblast at 50 Hz.
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Fatigue
Overall, pocket was found to have the smallest integral and shortest half-time
(Table 4: Muscle ). With regards to integrals, the collagen group was found to be
significantly greater than the pocket group. No significant difference was found regarding
time to half maximum force production (Figure 15).

Table 4: Muscle Fatigue - Time to Half and Integral of Maximum Force Production
Surgical Group
Pocket
Collagen
Fibroblast
Control
Abs. Integral
17.48 + 10.78
60.90 + 7.64
45.94 + 10.72 44.17 + 8.14
(mV/s)
Time to Half
6.31 + 3.29
11.81 + 3.27
13.45 + 5.60
11.47 + 3.65
(s)

A)

80.00

25.00

*

70.00

20.00

60.00
50.00

15.00

40.00
30.00

*

10.00

20.00

Time (s)

Absolute Integral (mN/mg*s)

B)

Integral
Time

5.00

10.00
0.00

0.00
Pocket

Pocket + Collagen Pocket + Collagen
+ Myoblasts

Control

Stimualtion Frequency (Hz)
Figure 15: Time to Half and Integral of Maximum Force Production
Force produced in measured using maximum stimulation intensity and frequency for 30 seconds. The time
it takes to go from maximum force production to half of that is also show. A – Raw data trace of force
production using a data acquisition unit that stimulated the sciatic nerve and measured force using a force
transducer attached to the Achilles tendon of a mouse. B – Averaged normalized muscle force production,
using individual gastrocnemius weights, for each treatment group at (n=9 control, n=2 pocket, n=3
collagen, and n=4 cells). Data are presented as mean ± SE. * denotes p < 0.05 for pocket vs collagen with
regard to absolute integral.
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Overall, the collagen and control groups have a smaller percent change than the
fibroblast group which was smaller than the pocket group (Table 5). With regard to the
control, fibroblast, and collagen groups, the rate of percent change was similar before 10
second and then leveled off at differing rates (Figure 16).
Table 5: Percent Change in Fatigue Force Production
Force Production (%)
Time (s)
Pocket
Collagen
Fibroblast
100.0 + 0.0
100.0 + 0.0
100.0 + 0.0
0
79.2
+
15.7
89.6
+
3.9
83.8 + 2.2
1
69.5 + 26.2
84.0 + 4.4
80.2 + 5.0
2
60.7 + 34.0
77.8 + 5.4
75.5 + 8.0
3
56.4 + 33.8
71.2 + 6.9
70.6 + 10.5
4
51.8 + 33.2
64.4 + 8.1
65.7 + 11.3
5
48.2 + 30.3
58.8 + 9.6
60.9 + 11.5
6
42.0 + 27.5
54.3 + 10.5
56.0 + 11.1
7
36.0 + 23.4
50.7 + 11.1
51.2 + 10.9
8
31.3 + 20.5
48.2 + 11.6
47.7 + 11.1
9
28.3 + 18.3
46.1 + 11.5
45.0 + 11.1
10
25.2 + 16.6
45.1 + 11.0
36.9 + 7.1
11
21.9 + 14.8
44.1 + 10.5
33.9 + 6.7
12
19.7 + 13.2
43.1 + 9.9
34.3 + 8.6
13
17.5 + 11.8
42.2 + 9.3
33.5 + 10.0
14
16.5 + 10.1
41.2 + 8.7
31.4 + 10.3
15
14.5 + 9.8
39.9 + 8.4
30.0 + 10.7
16
12.9 + 8.8
38.9 + 7.9
28.6 + 11.2
17
11.8 + 7.9
40.7 + 4.5
26.7 + 11.2
18
10.6 + 7.4
40.1 + 3.5
24.4 + 11.1
19
9.7 + 6.7
38.4 + 3.2
23.8 + 11.1
20
8.5 + 6.4
37.3 + 2.8
23.1 + 11.6
21
7.7 + 5.9
35.8 + 2.7
22.3 + 12.4
22
6.6 + 5.8
34.5 + 2.5
21.6 + 12.5
23
6.1 + 4.8
32.8 + 2.9
20.5 + 12.9
24
5.2 + 4.1
31.7 + 2.9
20.0 + 13.2
25
4.4 + 3.8
30.2 + 3.1
24.5 + 17.4
26
3.7 + 3.3
29.2 + 3.1
23.8 + 16.9
27
3.1
+
2.9
28.1
+
2.9
23.4 + 17.3
28
2.6 + 2.6
26.9 + 3.2
23.1 + 17.5
29

Control
100.0 + 0.0
73.2 + 5.8
70.2 + 5.8
66.5 + 5.3
62.6 + 4.7
57.9 + 4.4
54.0 + 4.4
51.1 + 4.6
49.3 + 4.7
48.0 + 4.9
46.8 + 5.1
45.7 + 5.3
45.0 + 5.5
44.4 + 5.6
44.1 + 5.6
43.6 + 5.6
43.3 + 5.5
42.7 + 5.6
41.8 + 5.5
41.1 + 5.6
40.4 + 5.7
39.4 + 5.7
38.7 + 5.8
37.8 + 5.8
36.9 + 5.7
36.1 + 5.7
35.4 + 5.8
34.7 + 5.7
34.1 + 5.8
33.4 + 5.8
21

A)

Percent Change from Max (%)

B) 120.0%
100.0%

80.0%
Pocket *
60.0%

Collagen
Myoblast *

40.0%
Control

*

20.0%

0.0%
0

5

10

15
Time (s)

20

25

30

Figure 16: Percent Change in Fatigue Force Production
Force produced in measured using maximum stimulation intensity and frequency for 30 seconds. The
percentage is calculated using the average force production in the given time window divided by the max
force production in the 0 to 1sec time interval. A – Raw data trace of force production using a data
acquisition unit that stimulated the sciatic nerve and measured force using a force transducer attached to the
Achilles tendon of a mouse. B – Percent change in force production over a 30sec time interval (n=9 control,
n=2 pocket, n=3 collagen, and n=4 cells). Data are presented as mean ± SE. * denotes p < 0.05 for pocket
vs myoblast vs collagen/control.

Profunda Femoris Diameter
Overall, the collagen and fibroblast groups had the largest percent change in
diameter in the midzone (Table 6). Although the fibroblast group saw largest change in
diameter in each zone it was not statistically significant from the other surgical groups
(Figure 17). In the midzone, the fibroblast group was greater than the pocket group.
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Table 6: Percent Change in Diameter of Collateral Networks
Surgical Group
Reentry
Midzone
Pocket
19.4 + 5.6%
14.3 + 7.2%
Collagen
22.6 + 9.0%
38.1 + 10.1%
Fibroblast
35.2 + 6.4%
46.6 + 14.1%

A)

Percent Change in Dia,meter (%)

D)

Stem
31.6 + 8.8%
35.3 + 6.8%
38.4 + 8.0%

C)

B)

70.0%

*

60.0%
50.0%
40.0%

Pocket
Collagen
Fibroblast

30.0%

*

20.0%
10.0%
0.0%
Reentry

Midzone

Stem

Figure 17: Percent Change in Diameter comparing Surgical Groups
Diameters for each zone in the collateral network was compared within each surgical group with respect to
their control. A – Raw photo of the Profunda or stem zone at 4x magnification. B – Raw photo of the
midzone at 10x magnification. C – Raw photo of the Saphenous or reentry zone a 4x magnification. D –
Percent change in diameter for each surgical group with respect to their control (n=15 control, n=4 pocket,
n=5 collagen, and n=6 cells). Data are presented as mean ± SE. * denotes p < 0.05 for pocket vs fibroblast
in the midzone.
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Chapter 4: DISCUSSION
Clinical Significance
Since PAOD is a chronic disease with general symptoms that disproportionately affect an
already vulnerable group – the elderly – it is a challenging disease to address. Even though
exercise is effective in prolonging the disease’s onset, this disease can also make it painful to
exercise. Other options include oral vasoactive compounds and surgical stenting [26]. Oral
vasoactive compounds are cheap but can have secondary side effects that require close
monitoring. Stenting is a more invasive treatment and carries the dangers of inserting synthetic,
foreign materials in to the body.
These results from this study proposes another treatment by localizing arterial remodeling
and using materials made by the body. The transplantation of fibroblast-containing collagen
constructs under collateral networks of ligated mice was found to promote collateral enlargement
in the midzone. Though this study found that collagen constructs functionally improves muscle
force production with regard to intensity and frequency, it was not able to differentiate between
collagen-only constructs and fibroblast-containing collagen constructs.

Future Work
Since the 1980s, previous research focused on characterizing the factors contributing to
arteriogenesis [2]. The research in the past couple decades have tested those factors as single
growth factors and have transplanted cells that are known to secrete those factors, to determine
which ones are more effective or how much is needed to be effective [27]. The next wave a
research is to assess the functionality of all these treatments. One of the first functionality
assessments tested muscular exhausting or fatigue using a treadmill.
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More recent studies use DAQs to obtain muscle force production measurements. Starting
in the early 2010s, muscles were excised, stored in specialized solutions, and connected to two
force transducers to measure force production [23,30]. It was only in the past few years that
studies have directly attached the mouse to DAQs and electrically stimulated them to obtain
force production measurements to assess cardiovascular disease [7].
DAQ set-ups inherently allow more consistency in data collection than observational
studies and therefore it can decrease some variability. This study in particular, has demonstrated
the utility in assessing the functional viability for therapeutic treatments. It not only compares the
proposed treatment to the disease state without treatment but it can also produce control or nondisease state results. Furthermore, multiple metrics for muscle functionality –force production,
force intensity and fatigue – can comfortably and accurately be tested within one session, unlike
some previous methods. Since excising a muscle can cause damage and affect data, it is safer to
excise it after collecting force production measurements.

Limitations
Considering the complexity of this study there were many logistical limitations that
resulted in variations in many external factors.
First, to keep this project manageable, constructs were made by students whose focus
were to create the collagen constructs. Due to this, surgeries were scheduled around when
constructs could be made; this resulted in non-randomized data collection. Also, due to previous
commitments of other students, the constructs had to made by multiple people.
Additionally, considering how many projects were going on at the time, the mouse
selection was first-come, first-serve. This resulted in two mice types being used: Swiss Webster
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and colony mice. Inherently, the colony mice have more variation and contained both male and
female mice while the Swiss Websters’ were only female. Sex influences the vascular response
due to impaired vasodilation [8].

Procedural Improvements
After performing the protocol numerous times, there are many tips and reminders to
ensure an effective and efficient data collection session. The biggest suggestion would require
operators to familiarize themselves with contractile and kinetic properties of muscle to
understand why these metrics are used and recognize the results produced [13].
Throughout the study, the one error that created the longest delay is the slippage of the
suture connecting the muscle to the force transducer. In order to prevent the suture from slipping
off the Achilles tendon, cut the tip of the calcaneus to hold the suture knot in place. To prevent
the suture from slipping out of the force transducer, use a hook- rigging mechanism instead of
the clamp mechanism used now. This could be achieved by knotting the open end of the suture to
create a loop that can be secured to a hook rather than pinched between clamp.
After analyzing force-intensity production data many intensity intervals were found to be
redundant (see Appendix G). In order to save time collecting and analyzing the data, the 18
intervals at 0.25mV increments can instead be cut in half by stimulating every 0.5 mV from
0.5mV to 4.5mV.
Previous research indicates that the gastrocnemius muscle consists mostly of fast-twitch
muscle fibers [13]. This suggest data obtain would more closely resemble that of an EDL
muscle. Previous research has found that EDL-like muscles have a very unique force-frequency
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curve (Figure 18). Considering this, less points before 10 Hz and more points between 15Hz and
30 Hz can better predict the force-frequency relationship in the gastrocnemius muscle.

Figure 18: Force Frequency Curve of EDL Muscle
Considering the gastrocnemius muscle is mostly composed of fast twitch muscles it most likely that its forcefrequency curve will resemble that of the EDL [13].

With regard to fatigue, the most difficult task was identifying a way to intuitively present
and accurately analyze the data. No statistically significant differences or trends were found in
comparing area under the curve nor time to half of the max force. An educational active learning
protocol effectively depicted fatigue as a percentage of decline force over a period of time
(Figure 19). By taking an average of force production, in bin sizes of a second, from 0s to 30s of
the fatigue data collect a more intuitive graph can be depicted and more accurate statistics can be
taken.
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Figure 19: Rate of Force Production During Fatigue
Maximum force production declines with time. Slow twitch muscles decline at a slower rate than fast twitch muscles
[13].

28

REFERENCES
1.

Allaqaband, S, Kirvaitis R, Jan F, Tanvir B.. "Endovascular Treatment of Peripheral
Vascular Disease." Current problems in cardiology 34.9 (2009): 359-476. Print.

2.

Buschmann, I. and Schaper, W. "The pathophysiology of the collateral circulation
(arteriogenesis)." The Journal of Pathology, 190(3), pp.338-342. Print.

3.

Cao, R., Bråkenhielm, E., Pawliuk, R., Wariaro, D., Post, M.J., Wahlberg, E., Leboulch, P.
and Cao, Y. "Angiogenic synergism, vascular stability and improvement of hind-limb
ischemia by a combination of PDGF-BB and FGF-2." Nature medicine 9.5 (2003): 604613. Print

4.

Centers for Disease Control and Prevention. Heart Disease Fact. National Center for
Chronic Disease Prevention and Health Promotion, 2015. Web.

5.

Centers for Disease Control and Prevention. Peripheral Arterial Disease (PAD) Fact Sheet.
National Center for Chronic Disease Prevention and Health Promotion. 16 June 2016. Web.

6.

Chacon, R. "The influence of substrate stiffness and fibroblasts on outward remodeling in
collateral circuits." California Polytechnic State University San Luis Obispo (2013). Web.

7.

Chatel, B., Hourdé, C., Gondin, J., Fouré, A., Le Fur, Y., Vilmen, C., Bernard, M.,
Messonnier, L.A. and Bendahan, D. "Impaired muscle force production and higher
fatigability in a mouse model of sickle cell disease." Blood Cells, Molecules, and Diseases
(2017), Vol 63, pp. 37-44. Print.

8.

Gardner AW. Sex differences in claudication pain in subjects with peripheral arterial
disease. Med Sci Sports Exerc 34: 1695-1698, 2002.

9.

Go, J. "Influence of Myoblasts on Arteriogenesis in a Murine Chronic Hindlimb Ischemia
Mode." California Polytechnic State University San Luis Obispo (2014). Web.

29

10.

Hakimzadeh N, Verberne, HJ, Siebes M, Piek JJ. "The future of collateral artery research."
Current cardiology Reviews 10.1 (2014): 73-86. Print.

11.

Halabi, Abdul. "RISK FACTORS." Michigan Medical Report. St. Joseph Mercy Oakland,
30 January 2009. Web.

12.

Hallett, John W. “Occlusive Peripheral Arterial Disease.” Merck Manuals. Merck and Co.
January 2008. Web.

13.

Harvard Cornachione, A.S., Benedini-Elias, P.C.O., Polizello, J.C. "Characterization of
fiber types in different muscles of the hindlimb in female weanling and adult Wistar rats."
Acta histochemica et cytochemica 44.2 (2011): 43-50. Print.

14.

Head, S. I., and M. B. Arber. "An active learning mammalian skeletal muscle lab
demonstrating contractile and kinetic properties of fast-and slow-twitch muscle." Advances
in Physiology Education 37.4 (2013): 405-414. Print.

15.

Horie, N., Pereira, M.P., Niizuma, K., Sun, G., Keren‐Gill, H., Encarnacion, A., Shamloo,
M., Hamilton, S.A., Jiang, K., Huhn, S. and Palmer, T.D. "Transplanted Stem Cell‐
Secreted Vascular Endothelial Growth Factor Effects Poststroke Recovery, Inflammation,
and Vascular Repair." Stem cells 29.2 (2011): 274-285. Print.

16.

Husmann, I., Soulet, L., Gautron, J., Martelly, I. and Barritault, D. "Growth factors in
skeletal muscle regeneration." Cytokine & growth factor reviews 7.3 (1996): 249-258.
Print.

17.

Kobayashi, H., Shimizu, T., Yamato, M., Tono, K., Masuda, H., Asahara, T., Kasanuki, H.
Okano, T. "Fibroblast sheets co-cultured with endothelial progenitor cells improve cardiac
function of infarcted hearts." Journal of Artificial Organs 11.3 (2008): 141-147. Print.

30

18.

Kranenburg, A.R., Boer, W., Krieken, H.J., Mooi, W., Walters, J.E., Saxena, P.R., Sterk,
P.J., Sharma, H.S. "Enhanced expression of fibroblast growth factors and receptor FGFR1 during vascular remodeling in chronic obstructive pulmonary disease." American journal
of respiratory cell and molecular biology 27.5 (2002): 517-525. Print

19.

Kuraitis, D., Ebadi D., Zhang P., Rizzuto E., Vulesevic B., Padavan D.T., Al Madhoun A.,
McEwan K.A., Sofrenovic T., Nicholson K., Whitman S.C., Mesana T.G., Skerjanc I.S.,
Musarò A., Ruel1 M., and Suuronen E.J. "Injected matrix stimulates myogenesis and
regeneration of mouse skeletal muscle after ischaemic injury." European Cells and
Materials 24.175 (2012): 95. Print

20.

London Cardiovascular Clinic. Outcomes After Andioplasty. NICOR UCL PCI Report
2011. 5 February 2013. Web.

21.

McArdle, W.D., Katch, F.I. and Katch, V.L., "Exercise physiology." Medicine & Science in
Sports & Exercise 23.12 (1991): 1403.

22.

Melina, Remy. "Why Do Medical Researchers Use Mice?" LiveScience. 16 Nov. 2010.
Web.

23.

Moorwood, C., Liu, M., Tian, Z., Barton, E. R. "Isometric and Eccentric Force Generation
Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies."
JoVE (Journal of Visualized Experiments) 71 (2013): e50036-e50036. Print.

24.

Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S,
Després J-P, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT,
Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER
3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L,
Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani

31

SS, Willey JZ, Woo D, Yeh RW, Turner MB. “Heart disease and stroke statistics— At-aGlance.” American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Web. 17 December 2015
25.

Rooke TW, Wennberg PW. Diagnosis and Management of Diseases of the Peripheral
Arteries and Veins. In: Walsh RA, Simon DI, Hoit BD, et al., eds.: Hurst’s The Heart. 12e
ed. New York: McGraw Hill, 2007. Print.

26.

Rudofsky, G., and H. H. Van Laak. "Treatment costs of peripheral arterial occlusive
disease in Germany: a comparison of costs and efficacy." Journal of Cardiovascular
Pharmacology (1994): S22-25. Print.

27.

Schaper, W. and Scholz, D. "Factors regulating arteriogenesis". Arteriosclerosis,
Thrombosis, and Vascular Biology, 23(7), pp.1143-1151. Print

28.

Seiler, Christian, et al. "The human coronary collateral circulation: development and
clinical importance." European heart journal 34.34 (2013): 2674-2682.Simon-Yarza, T.,
Formiga, F.R., Tamayo, E., Pelacho, B., Prosper, F., and Blanco-Prieto, M.J. "Vascular
endothelial growth factor-delivery systems for cardiac repair: and overview." Theranostics
v.2(6) (2012): p.541-552. Print.

29.

Van Royen, N., Piek, J.J., Buschmann, I., Hoefer, I., Voskuil, M. and Schaper, W.
"Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive
disease." Cardiovascular research (2001): 543-553. Print.

30.

Wacker, M.J., Touchberry, C.D., Silswal, N., Brotto, L., Elmore, C.J., Bonewald, L.F.,
Andresen, J. and Brotto, M. "Skeletal Muscle, but not Cardiovascular Function, Is Altered
in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets." Frontiers in
Physiology (2016), 7. Print.

32

31.

Zimarino M, D’Andreamatteo M, Waksman R, Epstein SE, De Caterina R. "The dynamics
of the coronary collateral circulation." Nature Reviews Cardiology 11.4 (2014): 191-197.
Print

33

APPENDIX
Appendix A: Restraint, Ligation, and Suturing Protocol for Arteriogenesis in a Mouse
Model

1.0

PURPOSE

This protocol serves as a reference checklist to perform a surgical modification to a
mouse model of peripheral arterial occlusion (PAO) and deliver a cell therapy to
promote arteriogenesis by 1) properly restraining and intraperitoneally injecting
anesthetic to minimize trauma and pain, 2) skillfully performing a skin incision under a
stereomicroscope to minimize amount of stitches needed, 3) ligating the femoral artery
to model PAOD, 4) inserting a cell therapy construct to promote arteriogenesis and 5)
accurately suturing the incision to reduce infection.
2.0
Equipment
• Stereomicroscope
• Gloves (2 sets)
• Hot pack
• Bench covers
• Spray bottle of 70%
isopropyl alcohol (IPA)
• Spray bottle of
Nolvasan
• Syringe (1ml/10ml)
• Surgical tape
3.0

• Gauze Sponges (4x4
& 2x2)
• Surgical drapes
(20x20 & 16x20)
• Depilation cream
(Veet)
• Ophthalmic ointment
• Cotton Swabs
• Standard pattern
forceps
• Curved iris scissors

• Dumont #7 forceps
• Needle holders
• Prolene 7-0 Blue
monofilament suture
• C-1 13 mm 3/8 taper
suture needle
• Silk suture (1-2
inches)
• Cell therapy construct
• Retractor
• Autoclave tape

Methods

3.1 Basic Rules
a. Always set down forceps and scissors with tips up.
b. Hold instruments in any way to perform movement without contorting body and
compromising stability.
c. Maximize exposure and minimize trauma.
d. Keep back straight/good posture to get through long surgeries.
e. Saline. Saline. Saline. When you pull head out of scope, add saline.
f. Do not go over sterile fields.

3.2 Sterilized Instruments
Surgical drape (18-20inches
square).

Use autoclave tape to close tray
and wrap.
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3.3 Sterile pack
Prolene suture

4 cotton swabs

Silk ligature

surgical drape 16x20inches

3 4x4 gauze sponge

3.4 Open and activate hot pack
Weight mouse _______grams

3.5 Scruff Restrain and Injection
Grab base of mouse’s tail with dominant hand.
With fingertips (thumb & index) pinch scruff with
non-dominant hand.
Invert: pinch base tail with ring finger and use
middle finger to support its back.
Angle animal/nose downward.
Figure 1: Area of a) needle insertion-green
and b) depilation cream application-red.

Insert needle at a 30o angle (bevel side up)
(Figure 1a).
Pull back on syringe to confirm vacuum.
IP inject fluid/anesthesia. SubQ inject analgesia.
Paw pinch.

3.6 Depilation
Tape down mouse’s feet on 4x4 sponge gauze.
Rub cream going against the grain (Figure 1b).
Let rest for a couple minutes.
Remove with gauze sponge. Remove excess off

Figure 2: Incision above neurovascular
bundle to abdominal wall. (Note: this cut can
be made smaller than as seen in the picture.)

with Nolvasan.
Paw pinch.
Apply eye ointment and punch ear hole.
Move to fresh bench cover (heating pad).

3.7 Sterile set up
Open sterile tray away from bench
cover.
Open and dump contents of sterile
pack.
Wash hand up to elbow with
disinfectant soap

Put on sterile gloves.
Prep saline dish. (ask partner)
Move and put sterile drape over
mouse up to front paws.
Cut small window. Feel for hind
limb.

Put on isolation mask and cap.
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3.8 Skin Incision
Tent skin with standard pattern forceps.
With iris scissors, cut incisions perpendicular to
tented skin and above femoral vein and artery.
Keep cutting until past epigastria fat pad near

the

abdominal wall (~1 cm), see Figure 2.
Blunt dissect connective tissue using Dumont

#7

forceps.

3.9 Ligation
Blunt dissect to move epigastric fat pad.

Figure 3: Landmarks of the neurovascular bundle.

Gently remove connective tissue over
neurovascular bundle.
Separate artery from vein.
Note: Be aware of landmarks (Figure 3).
Ligate upstream from popliteal and
downstream from the epigastric.
Isolate artery with silk suture.
Tie off artery (2 knots).

3.10 Gracilis Pocket (Cell therapy construct)

Figure 4 Gracilis pocket landmarks for the cell therapy
construct.

Lightly jiggle muscle to see gracilis separation
Grab muscle gently at top margin.
Blunt dissect just underneath muscle.
Create small pocket for construct.
Reflect back pocket and carefully stuff collagen gel
underneath adductor muscle: see Figure 4

3.11 Suturing
DO NOT OVER TIGHTEN

Figure 5 Final product of all three knot types.

Using graph forceps pull skin back push suture through skin locked needle holders.
Surgeon square knot at bottom end of incision (6 knots).
Spiral sutures up the length of incision.
Instrument square knot (6 knots)
Cut off excess suture; see Figure 5 for final product.
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Date__________

Hindlimb Ischemia Surgery - Resection

Initials ________

Mouse Information
Mouse Information
DOB: ______________________

____22.
____23.
____24.
____25.

Sex: _______________________
Tag: _______________________

____26.
____27.

Genotype/strain: _____________

____28.

Cage: ______________________

____29.
____30.
____31.

Materials

____32.
____33.
____34.
____35.

Sterilize- autoclave or flash autoclave
____1.
____2.
____3.
____4.
____5.

forceps (2)
fine forceps (2)
ultrafine forceps (1)
fine scissors (1)
microscissors spring loaded (1)

____36.

____37.
Pre-sterilize in autoclave
____6.
____7.
____8.
____9.

cotton gauze (2)
cotton swabs (12)
6.0 silk suture (2 x 1-inch)
needle holder (1)

____38.
____39.
____40.

Spray surgery area with Nolvasan
Weigh animal in weight boat
Place animal in anesthesia box
Open the oxygen cylinder and set anesthesiamachine flow meter to ~3 l·min-1
Anesthetize animal w/ 5% isoflurane
Affix non-rebreathing circuit to bench-top with
tape
Reduce flow rate to 0.5-1.0 l·min-1 and the
isoflurane to 1-3%
Apply ear tag high on left ear
Lay animal supine with nose in nose-cone
Shave hair on the right hindlimb & lower
abdomen with clippers
Remove excess hair with depilatory cream
Spray right hindlimb with Nolvasan
Return animal to anesthesia box
Apply 4x4 gauze sponge to heat pad to protect
animal from excessive heat
Affix non-rebreathing circuit to surgery table w/
chemistry clamp

Lay animal supine on circulating heat pad w/
nose in nose-cone
Insert rectal probe and set thermo-controller to
37°C
Apply veterinary ointment to eyes to avoid
drying during procedure
Apply veterinary ointment to anus and place
rectal probe ~1cm into anus to monitor corebody temperature

Obtained in surgery suite
Surgery
____10.
____11.
____12.
____13.
____14.
____15.
____16.
____17.
____18.
____19.
____20.
____21.

sterile Petri dish w/ sterile saline
sterile gloves
sterile 7.0 prolene suture
heat-cautery
FST heat pad w/ rectal probe
heat pad
recovery bin & weigh boat
depilatory cream
non-sterile cotton swabs
non-sterile cotton gauze
isolation mask & cap
analgesic (Buprenorphine)

____41.
____42.
____43.
____44.
____45.

____46.
Surgery preparation

____47.

Make a small incision on the middle, medial
aspect of the left thigh
Extend the incision up to the abdominal wall
Blunt dissect the subcutaneous connective tissue
to maximize surgical exposure
Use cautery to remove fat pad overlying femoral
a-v pair & cauterize epigastric a-v pair
Blunt dissect the femoral artery-vein pair from
the nerve starting just upstream to the muscular
branch & extending to half-way between the
knee & ankle
Tie off the saphenous a-v pair with 6.0 silk
suture, halfway between the knee & ankle
Tie off the femoral a-v pair with 6.0 silk suture,
halfway just upstream to the muscular branch
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____48.

____49.
____50.
____51.
____52.
____53.

Grasping the distal ligature, use the cautery &
microscissors to remove the a-v pair up to the
upstream ligature
Gently rest cotton swabs on hemorrhage sites
Use 6.0 polypropylene suture to close the skin
Make a small incision on the middle, medial
aspect of the right thigh
Extend the incision up to the abdominal wall
Blunt dissect the subcutaneous connective tissue
to maximize surgical exposure

____57.

Indicate surgery on cage card

Notes
_____________________________________________
_____________________________________________
_____________________________________________
_____________________________________________

Post-Surgical
_____________________________________________
____54.
____55.

____56.

Give the animal an subcutaneous injection of
buprenorphine (0.075mg/kg)
Place the animal in the recovery bin, on a blue
bench cover, above a heat pad and allow to
recover
Turn flow meter down to 0, turn off isoflurane,
and close the oxygen cylinder

_____________________________________________
_____________________________________________
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Appendix B: Force Production and Atrophy of the Gastrocnemius and Immunohistology of
the Gracilis Muscle

1.0

PURPOSE

This protocol serves as a reference checklist to assess the efficacy of treating a ligated
artery mouse with the fibroblast cell construct by 1) dissecting and reflecting the sciatic
nerve for ease of stimulation of a muscle contraction and gently dissecting the Achilles
tendon to measure muscle force production of the gastrocnemius muscle, and 2)
removing the gracilis to stain and assess artery growth, and 3) removing the
gastrocnemius muscle to weigh and evaluate muscle atrophy.
2.0
Equipment
• Depilation cream
(Veet)
• Cotton Swabs
• Saline
• Gauze Sponges (4x4
& 2x2)
• Stereomicroscope
• Standard pattern
forceps
• Curved iris scissors
3.0
Methods

• Parafilm (1/8”-1/4”
strip)
• Silk suture (1-2
inches)
• Force transducer set
up
• Plastic cab tie
• Curved electrode
(current mA)
• Surgical tape

• Power lab/Laptop
• Paraformaldehyde
• Spray bottle of
Nolvasan
• Spray bottle of 70%
isopropyl alcohol (IPA)
• Syringe (1ml/10ml)
• Dumont #7 forceps
• Retractor

3.1 Depilation
Lay mouse on stomach and tape.
Apply Veet on the left side (medial and
laterally/dorsal and ventral).

3.2 Sciatic Dissection
Lay stomach down (dorsal)
Make incision hip and knee.
Blunt dissection tissue using scissors.

Figure 1: Area of adipose to lift

Cut laterally to maximize exposure and find triangle of adipose (Figure 1).

up.

Lift up adipose with #7 forceps and blunt dissect gap.
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Look for sciatic nerve (white) – clearly visible
outside of scope too.

3.3 Sciatic Reflection
Grab parafilm strip.
Place forceps under nerve from the top and grab
parafilm.
As seen in Figure 2.

Figure 2: Reflected sciatic nerve with
parafilm

Apply saline then cover with plastic wrap.

3.4 Achilles Dissection
Using graph forceps and iris scissors make skin
incision right above heel.
Gently blunt dissect and cut with iris scissors.
Cut of skin to improve visibility. Go farther than
heel.
Blunt dissect with #7 forceps.
Tie suture (2x) around tendon (see Figure 3).
Do NOT cut until connected to force transducer.

3.5 Force Transducer Setup (see Figure 4)

Figure 3: Achilles tendon with
suture placement.

Place mouse stomach up.
Use cable to attach hind paw to cross bar.

Figure 4: Force Transducer

Grab suture with standard patterns.
Attach suture to force transducer and cut

set-up and optimization.

tendon with iris scissors.
Using #7 pull sciatic nerve to wrap hook
electrode around it.
Tape down end of electrode.
Connect VNC cable to top output port (+).
Hook up PowerLab (as in 460)

3.6 Transducer Optimization
Center pinhole of transducer has to be right
above Achilles and gastrocnemius.
90o angle in all planes.
Electrode  PowerLab  Computer  Lab
Chart
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3.7 Gracilis Exposure
Place stomach up on surgical stage.
Make incision (is same place as ligation).
Extend using iris scissor blunt dissection.
Blunt dissect fat pad out of way.
Apply paraformaldehyde on gracilis muscle.
Cover with plastic crap.
Let sit for 20 minutes.

3.8 Gracilis Dissection Excision (anterior)

Figure 5: Gracilis dissection excision
landmarks.

Use gauze sponge to pick up extra
paraformaldehyde fixative.
Start dissecting near gracilis pocket top.
“Tunnel” above and below gracilis to free the whole muscle.
Blunt dissect under the anterior gracilis.
Blunt dissect outside saphenous and profunda.
Note: Do NOT go deep. Gracilis anterior is fairly thin.
Cut muscle with iris scissors outside of saphenous and
profunda (Figure 5).
Put muscle in centrifuge tube for post fixation.

3.9 Gastrocnemius Dissection Excision
Cut off skin between Achilles and gracilis to expose
gastrocnemius.
Can just peel away from hind limb using tendon.
Cut adductor muscle on top of gastrocnemius.

Figure 6: Separated
Gastrocnemius muscle.

Blunt dissect and cut using iris scissors to separate muscle. (See Figure 6).
Weight.
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Appendix C: PowerLab Optimization Protocol

Required Equipment
•
•
•
•
•
•
•
•
•
•
•
•
•
•

•
•

LabChart 7 software
PowerLab Data Acquisition Unit
Bridge Pod
Force Transducer
Small weight between 5–50 grams
Manipulator/Micropositioner and clamps
Ring stand
Chemistry clamp
Silk suture
Petri dish
One mouse
Saline
Small millimeter ruler
Tape
Muscle Stimulation Equipment
Vascular Clamp

Procedure
Equipment Setup and Calibration
1. Make sure the PowerLab is turned off and the USB cable is connected to the computer.
2. Connect the Force Transducer cable to the back of the Bridge Pod. Connect the Bridge Pod to Input 1
on the front panel of the PowerLab (Figure 7). Connect the Stimulating Electrodes to the output on
the front panel of the PowerLab. Follow the color scheme in Figure 7. Note that newer PowerLab

Systems do not rely on the Bridge Pod.
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Figure 7. Equipment Setup for PowerLab 26T

3. Securely mount the Force Transducer and Manipulator/Micropositioner on the Ring Stand.
4. Turn on the PowerLab.

Calibrating the Force Transducer
Raw output from the Force Transducer is in millivolts (mV). It needs to be calibrated to give the more
meaningful units of Newtons (N). The Force Transducer also has some residual offset voltage that needs
to be corrected for.

1. Launch LabChart and open the settings file “Frog Muscle Settings” from the Experiments tab in the
Welcome Center. It will be located in the folder for this experiment. ****BE SURE TO LOAD 2

WINDOWS, ONE FOR EACH LIMB****

2. Select Bridge Pod from the Channel 1 Channel Function pop-up menu. Leave the Force Transducer
undisturbed. Observe the signal (Figure 9) in the dialog. Zero this signal by turning the knob on the
front of the Bridge Pod. Close the Bridge Pod pop-up menu.
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Figure 9. Bridge Pod Dialog

3. Start recording. Record for five seconds, and then hang a known weight (between 5–50 grams,
provided by your instructor) from the Force Transducer. Record for a further five seconds, and Stop.
4. Click-and-drag to select all the data. Select Units Conversion from the Channel 1 Channel Function
pop-up menu (Figure 10).

Figure 10. Units Conversion Dialog

5. Select a small area when no weight was added, and click the arrow next to “Point 1.”
6. Select a small area when the weight was added, and click the arrow next to “Point 2.”
7. Enter the desired unit value in Newtons for each weight. Use the equation below:
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Exercise 1a: Twitch Recruitment
In this exercise, you will determine the effect of stimulus amplitude (strength) on contractile force- the
force-intensity relationship.

8. LabChart should be open. If not, open the settings file “Frog Muscle Settings.”
9. Make sure the muscle is moist and is in contact with the electrodes.
10. Zero the Bridge Pod. Use the same procedure as before. You do not need to calibrate the data.
Note: For this exercise, you will be running a macro to apply a series of increasing stimuli. A macro is a
recorded set of commands and operations that can be executed with a single command.
11. Go to the Macro menu and select Recruitment to start the macro. Alternatively, you can press F2.
LabChart will start recording, increase the stimulus on its own, and stop recording. (Do not click Start
before playing the macro.)
12. When the macro is finished, select “Save As” and save your data file to the desktop, but do not close
the file.
13. Scroll through your data and Autoscale, if necessary. Start at the end of the data and move toward
the beginning. Determine the minimum voltage required to elicit the maximum contraction; this is the
maximum excitation voltage.
14. Multiply this voltage by 1.5. This new value is the supramaximal stimulus voltage. The supramaximal
stimulus voltage will be used in each of the following exercises.
15. Wait at least 30 seconds before moving on to the next exercise. Keep the muscle moist with saline
solution.

Exercise 2: Optimizing Muscle Length
In this exercise, you will ensure that muscle length is optimal for force production.

1. Make sure the muscle is moist and the electrodes are still positioned correctly.
2. Zero the Bridge Pod as before. You do not need to calibrate the data.
3. Note the position of the Manipulator/Micropositioner using the ruler.
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4. Click on the data at the end of the last data block, and go to the Commands menu and select Add
comment. Type “exercise 2” and click Add.
5. Go to the Setup menu and select Stimulator Panel. In the Pulse Height text box, enter the value
(in volts) for the supramaximal stimulus voltage calculated in Exercise 1. Do not adjust any other
settings.
6. Select Start to initiate a single twitch and Stop to end the recording
7. Measure the force amplitude with the cursor
8. Lengthen the muscle by 1mm using the micromanipulator and repeat steps 6 & 7.
9. The optimal length has been reached once the force amplitude is unaltered for two successive twitch
forces.

Exercise 1b: Twitch Recruitment
In this exercise, you will determine the effect of stimulus amplitude (strength) on contractile force at
optimal length- the force-intensity relationship.

16. LabChart should be open. If not, open the settings file “Frog Muscle Settings.”
17. Make sure the muscle is moist and is in contact with the electrodes.
18. Zero the Bridge Pod. Use the same procedure as before. You do not need to calibrate the data.
Note: For this exercise, you will be running a macro to apply a series of increasing stimuli. A macro is a
recorded set of commands and operations that can be executed with a single command.
19. Go to the Macro menu and select Recruitment to start the macro. Alternatively, you can press F2.
LabChart will start recording, increase the stimulus on its own, and stop recording. (Do not click Start
before playing the macro.)
20. When the macro is finished, select “Save As” and save your data file to the desktop, but do not close
the file.
21. Scroll through your data and Autoscale, if necessary. Start at the end of the data and move toward
the beginning. Determine the minimum voltage required to elicit the maximum contraction; this is the
maximum excitation voltage.
22. If the maximal voltage is different than what was found in Exercise 1a, then multiply this voltage by
1.5 and use it throughout the remaining following exercises.

Exercise 3: Muscle Tetanus
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In this exercise, you will examine the impact of stimulus frequency on muscle force production- the forcefrequency relationship.

1. Make sure the muscle is moist and the electrodes are still positioned correctly.
2. Zero the Bridge Pod as before, but do not calibrate the data.
3. Click on the data at the end of the last data block, and go to the Commands menu and select Add
comment. Type “exercise 2” and click Add.
Note: For this exercise, you will be running a different macro to set up the Stimulator and record the
data. Do not click Start before playing the macro.
4. Go to the Macro menu and select Tetanus to start the macro. Alternatively, you can press F5.
LabChart will start recording and will prompt you with messages.
5. Follow the on-screen instructions. The PowerLab will stimulate the muscle for one second with
repetitive pulses at intervals of 400 ms, 200 ms, 100 ms, 50 ms, and then 20 ms. Each recording will
appear in a separate block.
6. When the macro has finished, add a comment to each block of data with the stimulus interval as
indicated above. Click on the data at the beginning of a data block, and go to the Commands menu
and select Add comment. Type the stimulus interval and select the comment to be inserted at the
selection.
7. Save your data. Do not close the file.
8. Wait at least 30 seconds before moving on to the next exercise. Make sure you keep the muscle
moist with saline solution.

Exercise 4: Muscle Fatigue
In this exercise, you will examine muscle fatigue, evoked by prolonged tetanic stimulation of the muscle
at 50 Hz for 30 seconds.

1. Make sure the muscle is moist and the electrodes are still positioned correctly.
2. Zero the Bridge Pod as before, but do not calibrate the data.
3. Click on the data at the end of the last data block, and go to the Commands menu and select Add
comment. Type “exercise 3” and click Add.
Note: For this exercise, you will be running a final macro to stimulate the muscle repetitively. Do not
click Start before playing the macro.
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4. Go to the Macro menu and select Fatigue to start the macro. Alternatively, you can press F6.
LabChart will start recording and will prompt you with messages.
5. Follow the on-screen instructions. The PowerLab will stimulate the muscle with a stimulus interval of
20 ms for 30 seconds. The recording duration of the macro is 45 seconds.
6. Save your data and close the file. Complete exercises 1-4 with the contralateral limb using
the second window you opened. If the same settings file/window is used, LabChart will
begin the recruitment macro at the last stimulus intensity used- tetanus- which is not
appropriate for a twitch.

Copyright © 2010 ADInstruments Pty Ltd. All rights reserved.

PowerLab® and LabChart® are registered trademarks of ADInstruments Pty Ltd. The names of specific
recording units, such as PowerLab 8/30, are trademarks of ADInstruments Pty Ltd. Chart and Scope
(application programs) are trademarks of ADInstruments Pty Ltd.

www.ADInstruments.
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Appendix D: -SMA Staining Protocol
Materials
24-well culture plates (Cat#: 3738, Corning Incorporated)
PBS
0.1% Saponin (Cat#: 47036, Sigma-Aldrich)
2% Bovine Serum Albumin (Cat# B6917, Sigma Aldrich)
Monoclonal Anti-Alpha Smooth Muscle Actin, Cy3 Conjugate (Cat#: C6198, Sigma-Aldrich)
Slides
Coverslips
Parafilm
Aluminum foil
Staining
1. Using forceps, remove muscle from PBS (stored in microcentrifuge tube at 4°C) and place in a
single well of a 24-well culture plate.
2. Prepare antibody solution containing 1:200 1A4 clone (alpha-smooth muscle actin, Cy3
conjugate) in 0.1% saponin (reconstituted in PBS), 2% BSA (reconstituted in PBS) in PBS,
using 0.3mL of solution per muscle.
3. Incubate muscle in antibody solution for 3 nights (72 hours) at 4°C). (Note: Critical step—3
nights crucial for bright staining) by gently pipetting solution over muscle.)
4. Wash in 0.1% saponin in PBS 3x for 20 minutes at room temperature. Cover plate with foil
during each wash.
5. Wash in plain PBS for 30 minutes. Cover with foil during each wash.
6. Place 1-2 drops of 50/50 PBS and Glycerol onto slide.
7. Remove muscle from well using forceps and place on a slide.
8. Add 1-2 drops of 50/50 PBS and Glycerol to the top of the muscle and place cover slips over
the
muscle.
9. Paint edges of coverslip with clear nail polish to create a seal and prevent tissue desiccation.
10. Store slides at 4°C wrapped in foil or an opaque container between imaging.
Imaging
11. Image using a standard fluorescent microscope. (Cy3 excitation: 550 nm, emission: 570 nm)
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Appendix E: Gracilis Image Acquisition and Quantification

1.0
PURPOSE
This protocol serves as a reference checklist to analyze and quantify the
paraformaldehyde fixed and fluorescent antibody stained alpha-smooth muscle actin of
mice gracilis muscle under a wide field fluorescence microscope by 1) photographing
three regions of collateral (stem, midzone, and reentry) and 2) analyzing their respective
diameters using ImageJ’s straight line tool.
2.0
Equipment
• Fluorescent stained gracilis muscle slide
• Computer

• Fluorescence Microscope
• ImageJ

3.0
Methods
3.1 Gracilis Image Acquisition
Obtain stained muscle slide from
ISA.
Place under fluorescent
microscope.
Focus slide through microscope
Open computer application.
Find profunda end of muscle.
Take a picture, rename, and save.

Move microscope field right
allowing for image overlap on the left
side.
Take a picture, rename, and save.
Repeat above 2 steps until you
have reached the far-sided saphenous.
Lay stomach down (dorsal)

3.2 Analysis of Gracilis Images
Open ImageJ
Open scale micrometer
Select straight-line tool
• Draw a line across
several graduations
• Measure line (length)
accordingly (in pixels)

Select Analyze
• Set scale
• Enter length (pixels)
• Enter known length
number
• Enter units (microns)

Use straight-line tool
(ctrl+m) to measure 3
regions shown in Figure 1:
• Collateral stem
• Collateral midzone
• Collateral reentery

Figure 1: Three regions of gracilis that are to be analyzed: stem, midzone, and reentry.
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Appendix F: Data Pad Lab Chart Reader Protocol for Data Acquisition

Lab Chart Reader: Data Acquisition
I.

Data Pad Protocol

Force-Intensity and Force-Frequency
1. Remove “M” marker from chart view.
2. In Data Pad toolbar, select Data Pad View
3. Set up needed columns according to Figure 1
a.

Click on the heading of Column A
i. Click Comments on left
ii. Click Full Comment Text on right
iii. Under Calculation Source: select Stimulus Marker from drop-down menu

b. Click on the heading of Column B
i. Click Selection & Active Point on left
ii. Click Time on right
c. Click on heading of Column C
i. Click Selection & Active Point on left
ii. Click Value on right
iii. Under Calculation Source: select Force from drop-down menu
d. Click on heading of Column C and D
i. Click Statistics on left
ii. Click Maximum Value on right
iii. Under Calculation Source: select Force from drop-down menu
e. To find the difference in Force Production
i. Change Data Pad to Cell edit mode in the top left corner of window signified
by red circle in Figure 1
ii. Click on the first cell in Column E (cell E1)
iii. Type “=D1-C1”
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Figure 1: Relevant Data for Force-Intensity Analysis

4. Return to Chart View Window
a. Select all data from Exercise 1B as shown in Figure 2
**Note: Be sure to select all data  from 0.0s in 0.25mV to 1.0ms in 50Hz

Figure 2: Selection of Exercise 1B in Chart View

5. To populate Data Pad
a. Select Multiple Add to Data Pad in Data Pad toolbar
i. In Select field input “1.0” s”
ii. For Step Through select Current Selection
iii. Click Add button.
6. Data values can then be copied and pasted into Excel
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Figure 3: Example Data Pad Output for Force-Intensity and -Frequency

II.

Fatigue
1. Place “M” marker at 0.00s in Fatigue window
2. Click anywhere on fatigue curve to set sample parameters
3. In Data Pad toolbar, select Data Pad View
4. Set up needed columns according to Figure 4
a. Click on Column G heading
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i. Click Selection & Active Point on left
ii. Click Time on Time on right
b. Column H to J
i. Click Statistics on left
ii. Click the relevant measurement for each column on the right
iii. Under Calculation Source: select Force from drop-down menu

Figure 4: Relevant Data Needed for Fatigue Analysis

5. Select Multiple Add to Data Pad in Data Pad toolbar
a. In Select field input “1.0” s”
b. For Step Through select Block containing selection
c. Click Add button.
6. Inactivate all other headings.
a. Click on column heading.
b. Select “Off”.
7. Data values can then be copied and pasted into Excel
**Note: use “Max Force Value” at 0.00s as 100% value when calculating percentages
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Figure 5: Example Data Pad Output for Fatigue
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Appendix G: Relevant Statistical Analysis for Force-Intensity Production Improvements
General Linear Model: Force versus Interval, Group
Method
Factor coding (-1, 0, +1)
Factor Information
Factor Type Levels Values
Interval Fixed
18 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75,
3.00, 3.25, 3.50, 3.75, 4.00, 4.25, 4.50
Group
Fixed
4 Cells, Collagen, Control, Pocket
Analysis of Variance
Source
DF Adj SS Adj MS F-Value P-Value
Interval
17 29.323 1.7249
5.96 0.000
Group
3 33.471 11.1571 38.58 0.000
Interval*Group 51 1.979 0.0388
0.13 1.000
Error
432 124.937 0.2892
Total
503 203.116
Model Summary
S R-sq R-sq(adj) R-sq(pred)
0.537779 38.49%
28.38%
12.66%

Fisher Pairwise Comparisons: Response = Force, Term = Interval
Grouping Information Using Fisher LSD Method and 95% Confidence
Interval
4.50
28
4.25
28
3.75
28
4.00
28
3.50
28
3.25
28
3.00
28
2.75
28
2.50
28
2.25
28
2.00
28
1.75
28
1.50
28
1.25
28
1.00
28
0.75
28
0.50
28
0.25
28

N
Mean
1.07992 A
1.05335 A
1.04894 A
1.04599 A
1.02427 A
1.00178 A
0.97665 A
0.93990 A
0.91738 A
0.86465 A
0.82123 A
0.81362 A
0.78538 A
0.73183
0.64969
0.53074
0.28455
0.06904

Grouping
B
B
B
B
B
B
B
B
B
B
B
B

C
C
C
C D
C D
C D
C D
C D
D E
E F
F

Means that do not share a letter are significantly different.
* NOTE * Cannot draw the interval plot for the Fisher procedure. Interval plots for
comparisons are illegible with more than 45 intervals.
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